SAM
MACK

Silverback Asset Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Silverback Asset Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-2,409
Closed -$166K – 54
2014
Q3 		$166K Sell
2,409
-1,353
-36% -$72.3K 0.02% 46
2014
Q2 		$216 Buy
+3,762
New +$191K 0.02% 59

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Silverback Asset Management's MACK Position: Q4 2014 in Review

Silverback Asset Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2014, closing a stake of 2,409 shares — an estimated $166K sold.

Silverback Asset Management first reported a position in MACK in Q2 2014 and held it in 2 quarters. The position peaked at $166K in Q3 2014. 143 funds tracked by Wall St. Rank hold MACK as of Q4 2014.

  • Silverback Asset Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2014 after selling out during the quarter.
  • Silverback Asset Management sold 2,409 Merrimack Pharmaceuticals, Inc. shares in Q4 2014, an estimated $166K.
  • Silverback Asset Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2014 and held it in 2 quarters.
  • Silverback Asset Management's Merrimack Pharmaceuticals, Inc. position peaked at $166K in Q3 2014.
  • 143 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2014.

Based on Silverback Asset Management's 13F filing for Q4 2014, filed 13 Feb 2015.